EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy

Ilaria Valentini, Gianni Ghetti, Marika Pane, Filippo Rumi, Eugenio Di Brino, Michele Basile, Gabriele Maria Pistillo, Matthias Bischof

The European Journal of Health Economics · 2026-02 · 27 (1) · 77-94

DOI: 10.1007/s10198-025-01806-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The European Journal of Health Economics, online erschienen am 26.06.2025. Verfasst von Ilaria Valentini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Economics, Cattolica del Sacro Cuore University (UCSC), Largo F, Vito 1, 00168, Rome, Italy. ilaria.valentini@unicatt.it. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Survival of Motor Neuron 2 Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Gene Therapies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: We assessed the cost effectiveness of onasemnogene abeparvovec (OA) for presymptomatic infants with two or three copies of the survival motor neuron 2 (SMN2) gene (diagnosed/treated ≤ 6 weeks old) who lack functional SMN1 gene (biallelic SMN1 mutations). This cost-utility model compared three disease-modifying treatments and best supportive care (BSC) (scenario analysis) in an Italian setting. METHODS: For a cohort of 1000 children, a Markov model simulated costs and benefits of OA (a one-time treatment), nusinersen and risdiplam (continuous lifelong treatments), and BSC. A lifetime time horizon (up to age 100 years) was applied, and the perspective of the Italian National Health Service was considered. Results are reported as incremental cost-effectiveness ratios (ICERs). Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the model and validity of results. RESULTS: In the full cohort, OA was dominant (less costly, more effective) compared with nusinersen or risdiplam (ICERs,-€4,562,815 and-€718,640), and cost effective (more costly, more effective) compared with BSC (ICER, €65,894). Similar results were found for patients with two SMN2 copies. For patients with three SMN2 copies, OA was less costly, with a similar efficacy profile compared with nusinersen, dominant versus risdiplam, and cost effective compared with BSC. Probabilistic sensitivity analysis demonstrated the robustness of the model and validated deterministic sensitivity analysis results for the full cohort. CONCLUSIONS: OA for the treatment of presymptomatic newborns was dominant or cost effective compared with other treatments or BSC in the full patient cohort within the Italian context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Atrophy, SpinalSurvival of Motor Neuron 2 ProteinHumansCost-Benefit AnalysisItalyMarkov ChainsInfant, NewbornOligonucleotidesQuality-Adjusted Life YearsMaleFemaleInfantSurvival of Motor Neuron 1 ProteinAzo CompoundsPyrimidines

Stichwörter der Autor:innen

Cost-effectiveness analysisEconomic evaluationNewborn screeningOnasemnogene abeparvovecPresymptomatic newbornsSpinal muscular atrophy

Substanzen

nusinersenSurvival of Motor Neuron 2 ProteinOligonucleotidesSMN2 protein, humanRisdiplamSurvival of Motor Neuron 1 ProteinAzo CompoundsPyrimidines

Autor:innen und Institutionen

  • Faculty of Economics, Cattolica del Sacro Cuore University (UCSC), Largo F, Vito 1, 00168, Rome, Italy. ilaria.valentini@unicatt.it.
  • Altems Advisory, Spin-off dell'Università Cattolica del Sacro Cuore, Rome, Italy. ilaria.valentini@unicatt.it.
  • AdRes HEOR s.r.l, Turin, Italy.
  • Pediatric Neurology Unit, Fondazione Policlinico Universitario "A. Gemelli," IRCCS, Rome, Italy.
  • Nemo Clinical Centre, Fondazione Policlinico Universitario "A. Gemelli," IRCCS, Rome, Italy.
  • Faculty of Economics, Cattolica del Sacro Cuore University (UCSC), Largo F, Vito 1, 00168, Rome, Italy.

Förderung

  • Novartis Gene Therapies

Zitieren

APA

Valentini, I., Ghetti, G., Pane, M., Rumi, F., Di Brino, E., Basile, M., Pistillo, G. M., & Bischof, M. (2026). Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy. The European Journal of Health Economics, 27(1), 77-94. https://doi.org/10.1007/s10198-025-01806-2

Vancouver

Valentini I, Ghetti G, Pane M, Rumi F, Di Brino E, Basile M, et al. Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy. The European Journal of Health Economics. 2026;27(1):77-94. doi:10.1007/s10198-025-01806-2

BibTeX
@article{Valentini2026,
  author = {Valentini, Ilaria and Ghetti, Gianni and Pane, Marika and Rumi, Filippo and Di Brino, Eugenio and Basile, Michele and Pistillo, Gabriele Maria and Bischof, Matthias},
  title = {Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy},
  journal = {The European Journal of Health Economics},
  year = {2026},
  volume = {27},
  number = {1},
  pages = {77--94},
  doi = {10.1007/s10198-025-01806-2}
}
Kostenlos starten →